公开(公告)号：US6066621A

公开(公告)日：2000-05-23

申请号：US475577

申请日：1995-06-07

Applicant: Michael Sela ,  Edna Mozes

Inventor： Michael Sela ,  Edna Mozes

IPC: A61K38/00 ,  A61K39/00 ,  A61P43/00 ,  C07K14/705 ,  G01N33/564 ,  G01N33/569

CPC classification number: C07K14/70571 ,  G01N33/564 ,  G01N33/56977 ,  A61K38/00 ,  A61K39/00

Abstract: Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor .alpha.-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthenogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

Abstract translation: 公开了具有至少九个氨基酸残基的肽，其各自包含对应于人乙酰胆碱受体α亚基的位置p200-208或p262-266，但与一个或多个氨基酸取代不同的氨基酸序列。 这些肽抑制人外周血淋巴细胞对重症肌无力肽p195-212和p259-271的增殖反应，适用于治疗重症肌无力患者。

公开(公告)号：US07858738B2

公开(公告)日：2010-12-28

申请号：US11894472

申请日：2007-08-20

Applicant: Edna Mozes

Inventor： Edna Mozes

IPC: A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  C07K7/00 ,  C07K14/00

CPC classification number: C07K16/18 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73

Abstract: Synthetic peptides of at least 12 and at most 30 amino acid residues comprising a sequence consisting of, or found within, a complementarity-determining region (CDR) found in the heavy or light chain of the human anti-DNA 16/6Id monoclonal antibody, or a sequence obtained by replacement and/or deletion and/or addition of one or more amino residues to said sequence, and salts, chemical derivatives and polymers of said peptides can be used for immunomodulation of systemic lupus erythematosus-associated responses.

Abstract translation: 包含由人抗-DNA 16 / 6Id单克隆抗体的重链或轻链中发现的互补决定区（CDR）组成或发现的序列的至少12个和至多30个氨基酸残基的合成肽， 或通过将所述序列替换和/或缺失和/或添加一个或多个氨基残基获得的序列，以及所述肽的盐，化学衍生物和聚合物可用于系统性红斑狼疮相关应答的免疫调节。

公开(公告)号：US06613536B1

公开(公告)日：2003-09-02

申请号：US08913994

申请日：1997-09-29

Applicant: Edna Mozes ,  Ari Waisman

Inventor： Edna Mozes ,  Ari Waisman

IPC: A61K3800

CPC classification number: G01N33/564 ,  A61K38/00 ,  A61K47/62 ,  C07K16/18 ,  C07K2317/73 ,  G01N2800/104

Abstract: Synthetic peptides based on a complementarity-determining region (CDR) of the heavy or light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease in mice, and analogs, and salts and chemical derivatives thereof; dual peptides comprising two such peptides or analogs covalently linked to one another either directly or through a short linking chain; peptide polymers comprising a plurality of sequences of said peptide or analog thereof; and peptide polymers attached to a macromolecular carrier, are disclosed, and pharmaceutical compositions comprising them for the treatment of SLE in humans.

Abstract translation: 基于诱导小鼠系统性红斑狼疮（SLE）样疾病的病原性抗DNA单克隆抗体的重链或轻链的互补决定区（CDR）的合成肽及其类似物及其盐及其化学衍生物 ; 包含两个这样的肽的双肽或直接或通过短连接链彼此共价连接的类似物; 包含所述肽或其类似物的多个序列的肽聚合物; 和与大分子载体连接的肽聚合物，以及包含它们的药物组合物用于治疗人类中的SLE。

公开(公告)号：US20100322928A1

公开(公告)日：2010-12-23

申请号：US12448937

申请日：2008-01-17

Applicant: Edna Mozes

Inventor： Edna Mozes

IPC: A61K39/395 ,  A61K31/573 ,  A61K31/5377 ,  A61K38/16 ,  A61K31/713 ,  A61P37/02 ,  A61P29/00 ,  C12Q1/68 ,  C40B30/04

CPC classification number: G01N33/564 ,  G01N2800/104

Abstract: A method of treating systemic lupus erythematosus (SLE) in a subject are provided. The method comprise altering in cells of the subject activity and/or expression of at least one gene selected from the group consisting of Mpo, Ltf, Lcn, Camp, Ngp, Slfn, Ctsg, Thbs1, S100a8, 1190003K14Rik, Prtn3, S100a9, Tfpi, Fzd6, Nid1, 5830484A20Rik, 5830484A20 LOC 545340, Tnfsf4, IPstpip2, Pigr, 270022B06Rik, L5R-alpha, A130040M12Rik, Gpr132, Cd8b1, Dhx9, Cyp11a1, Lmo7, Rnf184, Pstpip2, Hdgfrp3, Ass1 and Zbtb20, thereby treating SLE. Also provided are methods of diagnosing SLE and monitoring treatment of SLE.

Abstract translation: 提供了一种治疗受试者系统性红斑狼疮（SLE）的方法。 该方法包括在细胞中改变选自Mpo，Ltf，Lcn，Camp，Ngp，Slfn，Ctsg，Thbs1，S100a8，1190003K14Rik，Prtn3，S100a9，Tfpi中的至少一种基因的至少一种基因的表达和/ ，Fzd6，Nid1,5830484A20Rik，5830484A20 LOC 545340，Tnfsf4，IPstpip2，Pigr，270022B06Rik，L5R-α，A130040M12Rik，Gpr132，Cd8b1，Dhx9，Cyp11a1，Lmo7，Rnf184，Pstpip2，Hdgfrp3，Ass1和Zbtb20，从而治疗SLE。 还提供诊断SLE和监测SLE治疗的方法。

公开(公告)号：US20080119390A1

公开(公告)日：2008-05-22

申请号：US11894472

申请日：2007-08-20

Applicant: Edna Mozes

Inventor： Edna Mozes

IPC: A61K38/00 ,  C07K16/00 ,  C12Q1/20 ,  A61P43/00

CPC classification number: C07K16/18 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73

Abstract: Synthetic peptides of at least 12 and at most 30 amino acid residues comprising a sequence consisting of, or found within, a complementarity-determining region (CDR) found in the heavy or light chain of the human anti-DNA 16/6Id monoclonal antibody, or a sequence obtained by replacement and/or deletion and/or addition of one or more amino residues to said sequence, and salts, chemical derivatives and polymers of said peptides can be used for immunomodulation of systemic lupus erythematosus-associated responses.

Abstract translation: 包含由人抗-DNA 16 / 6Id单克隆抗体的重链或轻链中发现的互补决定区（CDR）组成或发现的序列的至少12个和至多30个氨基酸残基的合成肽， 或通过将所述序列替换和/或缺失和/或添加一个或多个氨基残基获得的序列，以及所述肽的盐，化学衍生物和聚合物可用于系统性红斑狼疮相关应答的免疫调节。

公开(公告)号：US5556754A

公开(公告)日：1996-09-17

申请号：US480525

申请日：1995-06-07

Applicant: Dinah S. Singer ,  Leonard Kohn ,  Edna Mozes ,  Motoyasu Saji ,  Jocelyn Weissman ,  Giorgio Napolitano ,  Fred D. Ledley

Inventor： Dinah S. Singer ,  Leonard Kohn ,  Edna Mozes ,  Motoyasu Saji ,  Jocelyn Weissman ,  Giorgio Napolitano ,  Fred D. Ledley

IPC: A61K31/00 ,  A61K31/145 ,  A61K31/17 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/505 ,  A61K31/513 ,  A61K31/515 ,  A61K45/00 ,  A61P17/00 ,  A61P29/00 ,  A61P43/00 ,  C12N15/09 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/564 ,  G01N33/569 ,  C07H21/04 ,  C12P19/34

CPC classification number: G01N33/56977 ,  A61K31/00 ,  A61K31/145 ,  A61K31/17 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/505 ,  A61K31/513 ,  G01N33/5047 ,  G01N33/5088 ,  G01N33/564 ,  G01N2800/24 ,  G01N2800/245 ,  Y10S514/863 ,  Y10S514/885

Abstract: The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of MHC Class I molecules. In particular the use of the drug methimazole to suppress expression of MHC Class I molecules in the treatment of autoimmune diseases and the prevention or treatment of rejection in a transplant recipient is disclosed. In addition in vivo and in vitro assays are provided for the assessment and development of drugs capable of suppressing MHC Class I molecules.

Abstract translation: 本发明提供了用于治疗哺乳动物自身免疫疾病和预防或治疗移植受体中的移植排斥的方法。 治疗方法涉及使用能够抑制MHC I类分子表达的药物。 具体地，公开了使用药物甲巯咪唑抑制MHC I类分子在治疗自身免疫性疾病中的表达以及预防或治疗移植受体中的排斥反应的用途。 另外还提​​供体内和体外测定用于评估和开发能够抑制MHC I类分子的药物。

公开(公告)号：US5871950A

公开(公告)日：1999-02-16

申请号：US460886

申请日：1995-06-05

Applicant: Dinah S. Singer ,  Leonard Kohn ,  Edna Mozes ,  Motoyasu Saji ,  Jocelyn Weissman ,  Giorgio Napolitano ,  Fred D. Ledley

Inventor： Dinah S. Singer ,  Leonard Kohn ,  Edna Mozes ,  Motoyasu Saji ,  Jocelyn Weissman ,  Giorgio Napolitano ,  Fred D. Ledley

IPC: A61K31/00 ,  A61K31/145 ,  A61K31/17 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/505 ,  A61K31/513 ,  A61K31/515 ,  A61K45/00 ,  A61P17/00 ,  A61P29/00 ,  A61P43/00 ,  C12N15/09 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/564 ,  G01N33/569 ,  C12Q1/02 ,  A01N61/00 ,  C12Q1/00 ,  G01N33/53

CPC classification number: G01N33/56977 ,  A61K31/00 ,  A61K31/145 ,  A61K31/17 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/505 ,  A61K31/513 ,  G01N33/5047 ,  G01N33/5088 ,  G01N33/564 ,  G01N2800/24 ,  G01N2800/245 ,  Y10S514/863 ,  Y10S514/885

Abstract: The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of MHC Class I molecules. In particular the use of the drug methimazole to suppress expression of MHC Class I molecules in the treatment of autoimmune diseases and the prevention or treatment of rejection in a transplant recipient is disclosed. In addition in vivo and in vitro assays are provided for the assessment and development of drugs capable of suppressing MHC Class I molecules.

Abstract translation: 本发明提供了用于治疗哺乳动物自身免疫疾病和预防或治疗移植受体中的移植排斥的方法。 治疗方法涉及使用能够抑制MHC I类分子表达的药物。 具体地，公开了使用药物甲巯咪唑抑制MHC I类分子在治疗自身免疫性疾病中的表达以及预防或治疗移植受体中的排斥反应的用途。 另外还提​​供体内和体外测定用于评估和开发能够抑制MHC I类分子的药物。

公开(公告)号：US5356779A

公开(公告)日：1994-10-18

申请号：US624730

申请日：1990-12-10

Applicant: Edna Mozes ,  Israel Pecht

Inventor： Edna Mozes ,  Israel Pecht

IPC: C07K14/705 ,  G01N33/564 ,  G01N33/569 ,  G01N33/567

CPC classification number: G01N33/56977 ,  C07K14/70571 ,  G01N33/564 ,  G01N2800/24

Abstract: As assay for the measurement of direct binding of a peptide that is a T-cell epitope to gene products of the major histocompatibility complex (MHC), classes I and II, on the surface of intact living antigen-presenting cells, is provided. The assay comprises incubating the labelled peptide with the cells, and monitoring the extent of binding by the addition of a probe that reacts with the ligand used to label the peptide. The assay is suitable for autoimmune diseases and other immunological disorders. Peptides having a sequence corresponding to a stretch of the sequence of the antigen relevant to an immunological disorder, or modifications thereof, which bind to gene products of MHC, but do not stimulate T-cells, are also useful for the treatment of said disorders.

Abstract translation: 作为测定作为T细胞表位的肽与主要组织相容性复合物（MHC）的基因产物的直接结合的测定，提供了完整的活抗原呈递细胞表面的I和II类。 该测定包括将标记的肽与细胞孵育，并通过加入与用于标记肽的配体反应的探针来监测结合的程度。 该测定适用于自身免疫疾病和其他免疫学疾病。 具有对应于与免疫学病症相关的抗原序列的序列的序列或其修饰，其与MHC的基因产物结合但不刺激T细胞也可用于治疗所述疾病。